Novartis (NVS) said Sunday that data from a new subgroup analysis of a phase 2 trial evaluating Kisqali, plus endocrine therapy, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer showed reduced risk of recurrence across all efficacy measures.

The company said data from the median follow-up of 44.2 months demonstrated that patients receiving Kisqali saw "consistent reductions" in risk of recurrence, with pre-menopausal and younger patients experiencing greater reductions than post-menopausal patients.

Tolerability also remained consistent as the study saw fewer treatment discontinuations from adverse events among pre-menopausal patients, Novartis added.

The company said data from the trial is set to be presented at Sunday medical meeting.